Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_2
1
20%
Ph phase_3
3
60%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (25.0%)
Phase 33 (75.0%)

Trials by Status

completed360%
active_not_recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
active_not_recruitingphase_3

Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3

NCT05222906
active_not_recruitingphase_2

Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension

NCT02843035
completedphase_3

Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease

NCT00553631
completedphase_3

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

NCT00943111
completed

Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)

NCT01136304

Clinical Trials (5)

Showing 5 of 5 trials
NCT05222906Phase 3

Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3

Active Not Recruiting
NCT02843035Phase 2

Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension

Active Not Recruiting
NCT00553631Phase 3

Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease

Completed
NCT00943111Phase 3

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

Completed
NCT01136304

Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5